{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:17:59Z","timestamp":1778069879888,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:14:08Z","timestamp":1768263248000},"page":"285-296.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T"],"prefix":"10.1016","volume":"26","author":[{"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Lengil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2031-3035","authenticated-orcid":false,"given":"Todd","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.clml.2026.01.006_bib0001","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2026.01.006_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081599","article-title":"Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations","volume":"16","author":"Blum","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2026.01.006_bib0003","unstructured":"United States Food and Drug Administration. KYMRIAH\u00ae (tisagenlecleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/107296\/download"},{"issue":"3","key":"10.1016\/j.clml.2026.01.006_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2026.01.006_bib0005","unstructured":"United States Food and Drug Administration. AUCATZYL\u00ae (obecabtagene autoleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/183463\/download"},{"key":"10.1016\/j.clml.2026.01.006_bib0006","unstructured":"United States Food and Drug Administration. TECARTUS\u00ae (brexucabtagene autoleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"10.1016\/j.clml.2026.01.006_bib0007","unstructured":"United States Food and Drug Administration. YESCARTA\u00ae (axicabtagene ciloleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"10.1016\/j.clml.2026.01.006_bib0008","unstructured":"United States Food and Drug Administration. BREYANZI\u00ae (lisocabtagene maraleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"10.1016\/j.clml.2026.01.006_bib0009","unstructured":"United States Food and Drug Administration. ABECMA\u00ae (idecabtagene vicleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"10.1016\/j.clml.2026.01.006_bib0010","unstructured":"United States Food and Drug Administration. CARVYKTI\u00ae (ciltacabtagene autoleucel) - Prescribing Information. Accessed: May 12, 2025. https:\/\/www.fda.gov\/media\/107296\/download"},{"issue":"1","key":"10.1016\/j.clml.2026.01.006_bib0011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-023-00982-8","article-title":"Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies","volume":"30","author":"Yang","year":"2023","journal-title":"J Biomed Sci"},{"issue":"Suppl 3","key":"10.1016\/j.clml.2026.01.006_bib0012","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"20","key":"10.1016\/j.clml.2026.01.006_bib0013","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.006_bib0014","unstructured":"United States Food and Drug Administration. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. 2023. Accessed: April 28, 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous"},{"issue":"8","key":"10.1016\/j.clml.2026.01.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.01.006_bib0016","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.01.006_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-025-01676-4","article-title":"Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies","volume":"18","author":"Umyarova","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.01.006_bib0018","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtct.2024.06.027","article-title":"Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma","volume":"30","author":"Lorenc","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2026.01.006_bib0019","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/bjh.19590","article-title":"Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: a report from the Italian CART-SIE study","volume":"205","author":"Barone","year":"2024","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2026.01.006_bib0020","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-Cell Therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clml.2026.01.006_bib0021","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/bloodadvances.2024012573","article-title":"Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy","volume":"8","author":"Melody","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2026.01.006_bib0022","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s44321-024-00183-2","article-title":"CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts","volume":"17","author":"Berg","year":"2025","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clml.2026.01.006_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2026.01.006_bib0024","unstructured":"American Association For Cancer Research. Risk of secondary cancers after CAR T therapy may Be similar to Risk after other cancer treatments. https:\/\/www.aacr.org\/about-the-aacr\/newsroom\/news-releases\/risk-of-secondary-cancers-after-car-t-therapy-may-be-similar-to-risk-after-other-cancer-treatments\/#:\u223c:text=Four%20of%20the%20clinical%20trials,long%20enough%20to%20do%20so."},{"issue":"2","key":"10.1016\/j.clml.2026.01.006_bib0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-T-cell therapy: a review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.01.006_bib0026","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/MLR.0b013e318289c3fb","article-title":"An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data","volume":"53","author":"Whyte","year":"2015","journal-title":"Med Care"},{"issue":"6 (Supplement","key":"10.1016\/j.clml.2026.01.006_bib0027","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.jval.2024.03.885","article-title":"Validation of an algorithm to identify HR+\/HER2- metastatic breast cancer in claims data","volume":"27","author":"Chin","year":"2024","journal-title":"Value in Health"},{"issue":"1","key":"10.1016\/j.clml.2026.01.006_bib0028","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"11","key":"10.1016\/j.clml.2026.01.006_bib0029","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/aje\/kwae023","article-title":"Targeted learning with an undersmoothed LASSO propensity score model for large-scale covariate adjustment in health-care database studies","volume":"193","author":"Wyss","year":"2024","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2026.01.006_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/CCI.19.00094","article-title":"Frailty in older adults with multiple myeloma: a study of US veterans","volume":"4","author":"Patel","year":"2020","journal-title":"JCO clin cancer inform"},{"issue":"1","key":"10.1016\/j.clml.2026.01.006_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-022-03857-y","article-title":"Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study","volume":"21","author":"Zhou","year":"2023","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.clml.2026.01.006_bib0032","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.21037\/jtd-21-915","article-title":"Long-term radiation therapy-related risk of second primary malignancies in patients with lung cancer","volume":"13","author":"Han","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.clml.2026.01.006_bib0033","series-title":"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs","article-title":"Cancer-related hospitalizations for adults, 2017","author":"Roemer","year":"2006"},{"issue":"1","key":"10.1016\/j.clml.2026.01.006_bib0034","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/hematology.2021000284","article-title":"Diagnosis and therapeutic decision-making for the neutropenic patient","author":"Connelly","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.clml.2026.01.006_bib0035","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2026.01.006_bib0036","unstructured":"No evidence that CAR T cell therapy causes secondary cancers, Penn study finds. Accessed: May 9, 2025. https:\/\/www.pennmedicine.org\/news\/news-releases\/2025\/february\/no-evidence-that-car-t-cell-therapy-causes-secondary-cancers"},{"issue":"22","key":"10.1016\/j.clml.2026.01.006_bib0037","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.01.006_bib0038","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.01.006_bib0039","unstructured":"FDA Requires Boxed Warning for T Cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies. U.S. Food and Drug Administration; 2024 https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed."},{"issue":"22","key":"10.1016\/j.clml.2026.01.006_bib0040","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.01.006_bib0041","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clml.2026.01.006_bib0042","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.clml.2026.01.006_bib0043","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1016\/S2352-3026(23)00212-0","article-title":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","volume":"10","author":"Trab","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.clml.2026.01.006_bib0044","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1200\/JCO.2008.21.1920","article-title":"Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort","volume":"27","author":"Meadows","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.01.006_bib0045","article-title":"Second primary malignancies in diffuse large B-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy","volume":"7","author":"Rock","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.01.006_bib0046","doi-asserted-by":"crossref","first-page":"10897","DOI":"10.1182\/blood-2022-158013","article-title":"Incidence of second primary malignancies (SPMs) in patients in the US with triple-class-exposed (TCE) relapsed or refractory multiple myeloma (RRMM)","volume":"140","author":"Ge","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.006_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113403","article-title":"Secondary malignancies among mantle cell lymphoma patients","volume":"195","author":"Abalo","year":"2023","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clml.2026.01.006_bib0048","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018","volume":"11","author":"Dinnessen","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.01.006_bib0049","unstructured":"Kaur G, Riva E, Chhabra S, Rosenthal A, Fonseca R Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma. 2024. Accessed: May 9, 2025. https:\/\/rafaelfonseca.substack.com\/p\/incidence-or-t-cell-lymphoma-in-patients."},{"key":"10.1016\/j.clml.2026.01.006_bib0050","unstructured":"FDA Roundup: January 23, 2024. U.S. Food and Drug Administration; 2024. Accessed: March 28, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-roundup-january-23-2024"},{"key":"10.1016\/j.clml.2026.01.006_bib0051","unstructured":"CAR T benefits in cancer outweigh potential risk of secondary malignancies. January 18, 2024. Accessed: May 9, 2025. https:\/\/www.targetedonc.com\/view\/car-t-benefits-in-cancer-outweigh-potential-risk-of-secondary-malignancies"},{"issue":"2","key":"10.1016\/j.clml.2026.01.006_bib0052","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clml.2026.01.006_bib0053","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The fate(s) of CAR T-cell therapy: navigating the risks of CAR+ T-cell malignancy","volume":"5","author":"Abou-El-Enein","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10.1016\/j.clml.2026.01.006_bib0054","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-023-05095-8","article-title":"Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors","volume":"102","author":"Zhan","year":"2023","journal-title":"Ann Hematol"},{"issue":"16 (Supplement)","key":"10.1016\/j.clml.2026.01.006_bib0055","article-title":"Second primary malignancy (SPM) in patients (pts) with multiple myeloma (MM) receiving chimeric antigen receptor T-cell (CAR T) therapy or other systemic anticancer therapy (SACT): a comparative study using a real-world database","volume":"43","author":"Suvannasankha","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:39:49Z","timestamp":1778067589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S215226502600008X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}